In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, raised $85 million by offering 6.5 million shares at $13, within the range of $12 to $14. At pricing, the company commands a fully diluted market value of $364 million. Metacrine plans...read more
Updated Monday, 9/14. The post-Labor Day IPO frenzy is here as 14 IPOs plan to raise $7.8 billion in the coming week, led by cloud data unicorn Snowflake (SNOW). It is expected to be the biggest week for the IPO market by...read more
Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $85 million by offering 6.5 million shares at a price range of $12 to $14. At the midpoint of...read more
US IPO Weekly Recap: Snowflake's IPO breaks records in a diverse 15 IPO week
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
NASH biotech Metacrine prices IPO at $13 midpoint
Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, raised $85 million by offering 6.5 million shares at $13, within the range of $12 to $14. At pricing, the company commands a fully diluted market value of $364 million. Metacrine plans...read more
US IPO Week Ahead: The IPO market braces for a September SNOWstorm in a 14 IPO week
Updated Monday, 9/14. The post-Labor Day IPO frenzy is here as 14 IPOs plan to raise $7.8 billion in the coming week, led by cloud data unicorn Snowflake (SNOW). It is expected to be the biggest week for the IPO market by...read more
NASH biotech Metacrine sets terms for $85 million IPO
Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $85 million by offering 6.5 million shares at a price range of $12 to $14. At the midpoint of...read more